Fishman, M., Dutcher, J. P., Clark, J. I., Alva, A., Miletello, G. P., Curti, B., . . . McDermott, D. F. (2019). Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): Data from the PROCLAIM(SM) registry. J Immunother Cancer.
Citação norma ChicagoFishman, M., et al. "Overall Survival By Clinical Risk Category for High Dose Interleukin-2 (HD IL-2) Treated Patients With Metastatic Renal Cell Cancer (mRCC): Data From the PROCLAIM(SM) Registry." J Immunother Cancer 2019.
ציטוט MLAFishman, M., et al. "Overall Survival By Clinical Risk Category for High Dose Interleukin-2 (HD IL-2) Treated Patients With Metastatic Renal Cell Cancer (mRCC): Data From the PROCLAIM(SM) Registry." J Immunother Cancer 2019.